TABLE 3.
Ongoing CAR T cell-based clinical trials in patients with GBM.
| Molecular target | Clinical trial identifier and title | Study phase | CAR T cell dosage (+ combination) | Sponsor/Site (+ collaborators) | Estimated enrolment | Estimated primary completion date |
| B7-H3 |
NCT04385173 Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma |
1 | Three intratumoral or intracerebroventricular injections of CAR T cells at two doses in between temozolomide cycles. | Second Affiliated Hospital, School of Medicine, Zhejiang University [BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. (China)] | 12 | May, 2022 |
|
NCT04077866 B7-H3 CAR-T for Recurrent or Refractory Glioblastoma |
1/2 | Three intratumoral or intracerebroventricular injections of CAR T cells at two doses in between temozolomide cycles. | Second Affiliated Hospital of Zhejiang [Ningbo Yinzhou People’s Hospital, Huizhou Municipal Central Hospital, BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. (China)] | 40 | June, 2024 | |
| CD147 |
NCT04045847 CD147-CART Cells in Patients With Recurrent Malignant Glioma |
1 | Intracavity injection of CAR T cells, once per week for three weeks. | Xijing Hospital | 31 | October, 2020 |
| GD2 |
NCT04099797 C7R-GD2.CART Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) |
1 | Intravenous injection of between 1x107 – 1x108 CAR T cells with or without lymphodepletion chemotherapy. | Baylor College of Medicine (Center for Cell and Gene Therapy, Baylor College of Medicine) | 34 | February, 2023 |
| EGFRvIII |
NCT03726515 CART-EGFRvIII + Pembrolizumab in GBM |
1 | CART-EGFRvIII + pembrolizumab. | University of Pennsylvania | 7 | December, 2020 |
|
NCT03283631 Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (INTERCEPT) |
1 | Starting dose of 2.5 × 108 per CAR T cells per intracerebral infusion, with doses escalated in successive cohorts. | Duke University (National Cancer Institute, Duke Cancer Institute) | 24 | December, 2021 | |
| IL13Ra2 |
NCT02208362 Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma |
1 | IL13Rα2-specific, hinge-optimized, 41BB/truncated CD19- expressing CAR T cells by intratumoral, intracavitary, or intraventricular catheter. Weekly for three weeks with additional infusions if eligible. | City of Hope Medical Center (National Cancer Institute, Food and Drug Administration) | 92 | January, 2021 |
|
NCT04003649 IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma |
1 | Intravenous administration of nivolumab and ipilimumab followed by intracranial intraventricular/intracranital intratumoral infusion of CAR T cells. Up to four cycles. | City of Hope Medical Center (National Cancer Institute) | 60 | December, 2022 | |
| MMP2 (Chlorotoxin) |
NCT04214392 Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma |
1 | Three weekly cycles of one or two CAR T cell infusions. | City of Hope Medical Center (National Cancer Institute) | 36 | February, 2023 |
| Variable |
NCT03423992 Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas |
1 | CAR T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2 or GD2, with or without anti- PD-L1 mAb. | Xuanwu Hospital [Beijing Mario Biotech Company, Hebei Senlang BIotech Company, Beijing HuiNengAn Biotech Company (China)] | 100 | January, 2021 |